TY - JOUR
T1 - BBIBP-CorV (Sinopharm) vaccination- induced immunity is affected by age, gender and prior COVID-19 and activates responses to spike and other antigens
AU - Hasan, Zahra
AU - Masood, Kiran I.
AU - Qaiser, Shama
AU - Khan, Erum
AU - Hussain, Areeba
AU - Ghous, Zara
AU - Khan, Unab
AU - Yameen, Maliha
AU - Hassan, I
AU - Nisar, Muhammad Imran
AU - Qazi, Muhammad Farrukh
AU - Masooq, Haris
AU - Ali, Shiza
AU - Baloch, Sadaf
AU - Bhutta, Zulfiqar Ahmed
AU - Mahmood, Syed Faisal
AU - Hussain, Rabia
AU - Ghias, Kulsoom
PY - 2022/12/2
Y1 - 2022/12/2
N2 - Long-term solutions against SARS-CoV-2 infections require understanding of immune protection induced by different vaccine COVID-19 formulations. We investigated humoral and cellular immunity induced by Sinopharm (BBIBP-CorV) in a region of high SARS-CoV-2 seroprevalence.Levels of IgG antibodies to SARS-CoV-2 spike protein and its receptor-binding domain (RBD) were determined 24-weeks. Cellular immunity was investigated using a commercially available IFN-γ release assay to SARS-CoV-2 spike (Ag1 and 2) and extended genome antigens (Ag3).Increasing IgG seropositivity to Spike protein and RBD was observed post-vaccination. Seropositivity was reduced in those over 50 years and raised in females and those with prior COVID-19. After 20 weeks post-vaccination, only one third of participants had positive T cell responses to SARS-CoV-2 antigens. Prior COVID-19 impacted IFNγ responses, with reactivity enhanced in those infected earlier. The frequency of IFNγ responses was highest to extended genome antigen set.Overall, BBIBP-CorV- induced antibody responses were impacted by age, gender and prior COVID-19. Cellular immunity was present in a limited number of individuals after 20 weeks but was enhanced by prior infection. This suggests the need for booster vaccinations in older individuals. BBIBP-CorV-induced cellular activation is broader than to spike, requiring further study to understand how to monitor vaccine effectiveness.
AB - Long-term solutions against SARS-CoV-2 infections require understanding of immune protection induced by different vaccine COVID-19 formulations. We investigated humoral and cellular immunity induced by Sinopharm (BBIBP-CorV) in a region of high SARS-CoV-2 seroprevalence.Levels of IgG antibodies to SARS-CoV-2 spike protein and its receptor-binding domain (RBD) were determined 24-weeks. Cellular immunity was investigated using a commercially available IFN-γ release assay to SARS-CoV-2 spike (Ag1 and 2) and extended genome antigens (Ag3).Increasing IgG seropositivity to Spike protein and RBD was observed post-vaccination. Seropositivity was reduced in those over 50 years and raised in females and those with prior COVID-19. After 20 weeks post-vaccination, only one third of participants had positive T cell responses to SARS-CoV-2 antigens. Prior COVID-19 impacted IFNγ responses, with reactivity enhanced in those infected earlier. The frequency of IFNγ responses was highest to extended genome antigen set.Overall, BBIBP-CorV- induced antibody responses were impacted by age, gender and prior COVID-19. Cellular immunity was present in a limited number of individuals after 20 weeks but was enhanced by prior infection. This suggests the need for booster vaccinations in older individuals. BBIBP-CorV-induced cellular activation is broader than to spike, requiring further study to understand how to monitor vaccine effectiveness.
U2 - 10.1101/2022.11.30.518633
DO - 10.1101/2022.11.30.518633
M3 - Article
JO - Department of Pathology and Laboratory Medicine
JF - Department of Pathology and Laboratory Medicine
ER -
